Intermediatebiotechnology

Cystic Fibrosis Genetics

Overview

Cystic fibrosis is the classic autosomal recessive disorder: mutations in CFTR (chromosome 7) disable the chloride channel, dehydrating airway mucus and causing lung infections, pancreatic insufficiency, and male infertility. DeltaF508 (70% of alleles) deletes one phenylalanine, misfolding the protein. Carrier frequency ~1/25 in Northern Europeans; newborn screening, modulators (Trikafta), and gene-therapy research define modern care.

Learning objectives

  • Describe CFTR function and mutation effects
  • Explain deltaF508
  • Calculate carrier and recurrence risks
  • Explain modulator therapies

CFTR: the chloride channel

CFTR is an ATP-gated chloride channel in airway, pancreatic, sweat-duct, and vas deferens epithelia. Loss of function -> dehydrated secretions: thick mucus plugs airways (chronic Pseudomonas infection), blocks pancreatic ducts (malnutrition), raises sweat chloride (diagnostic test).

Channelopathy

CF is a channelopathy: one ion channel's failure cascades into multi-organ disease.

DeltaF508 and mutation classes

deltaF508 (c.1521_1523delCTT): loss of phenylalanine 508 -> protein misfolds, degraded by ER quality control (class II). ~2,000 CFTR variants in six classes: production (I), processing (II), gating (III), conductance (IV), quantity (V), stability (VI). Class guides modulator choice.

70% of alleles

deltaF508's frequency reflects a founder effect in European populations.

Inheritance and population genetics

Autosomal recessive: carrier parents -> 25% affected, 50% carrier per pregnancy. q^2 = 1/2500 (N. European births) -> q = 1/50, carriers ~1/25. Carrier screening panels cover common variants; residual risk calculations follow negative screens.

1 in 25 carriers

CF carrier screening is routine in pregnancy care in high-frequency populations.

Treatment revolution

Airway clearance, enzymes, antibiotics historically. Ivacaftor (2012, gating mutations), then Trikafta (elexacaftor/tezacaftor/ivacaftor, 2019): correctors + potentiator rescue deltaF508, transforming prognosis for ~90% of patients. Gene therapy/editing aims at the rest.

From symptomatic to molecular

Trikafta treats the protein defect itself: a template for other genetic diseases.

Key points

  • CFTR chloride channel loss -> dehydrated secretions, multi-organ disease
  • deltaF508: misfolding (class II), 70% of alleles
  • AR: 25% recurrence; carriers ~1/25 (N. European)
  • Trikafta (modulators) rescues most patients

Common misconceptions

✗ Myth: CF carriers have mild symptoms.

✓ Truth: Carriers are asymptomatic (possibly slight salt loss); disease needs two mutant alleles.

✗ Myth: All CF patients respond to Trikafta.

✓ Truth: ~90% carry responsive variants; nonsense/minimal-function patients await gene therapy.

Practice questions

Q1. Cystic fibrosis is inherited as
  1. Autosomal dominant
  2. Autosomal recessive
  3. X-linked
  4. Mitochondrial
Answer: B.

Two mutant CFTR alleles required; carriers healthy.

Q2. deltaF508 causes CFTR to
  1. Overactivate
  2. Misfold and be degraded
  3. Duplicate
  4. Move to nucleus
Answer: B.

Class II processing mutation: ER quality control destroys it.

Q3. If q^2 = 1/2500, carrier frequency is about
  1. 1/2500
  2. 1/25
  3. 1/50
  4. 1/10
Answer: B.

From q^2 = 1/2500, q = 1/50; carrier frequency = 2pq ≈ 2 × 1/50 = 1/25 in Northern Europeans.

Q4. Trikafta works by which mechanism?
  1. Editing DNA
  2. Correcting and potentiating mutant CFTR protein
  3. Replacing lungs
  4. Killing bacteria only
Answer: B.

Small molecules rescue folding (correctors) and gating (potentiator).

Click a question to reveal the answer and explanation.

Frequently asked questions

Why the sweat test?

CFTR also reabsorbs sweat chloride: elevated sweat Cl- (>60 mmol/L) diagnoses CF physiologically.

What is CBAVD?

Congenital bilateral absence of the vas deferens: CFTR-related male infertility, often the mildest CFTR phenotype.

Why did deltaF508 become common?

Possible heterozygote advantage (cholera/typhoid resistance hypotheses) or founder effects: debated.